ArticleCureus2025
Midventricular Obstruction With Diastolic Paradoxic Jet Flow in Transthyretin Cardiac Amyloidosis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthyretin (ATTR) cardiac amyloidosis has attracted clinical attention because of the development of practical identification and effective treatment. Since one of the initial manifestations of this condition is ventricular hypertrophy, the differential diagnosis includes hypertrophic cardiomyopathy (HCM). Midventricular obstruction (MVO) accompanied by paradoxic jet flow (PJF), which is an early diastolic flow from the apex to the base of the left ventricle, has been observed almost exclusively in HCM. Here, we report a case of ATTR cardiac amyloidosis with MVO and PJF. An 81-year-old woman presented with exertional dyspnea. Echocardiography showed biventricular hypertrophy, MVO with a peak flow velocity of 3.1 m/s in the mid-left ventricle, and PJF. A diagnosis of not HCM but wild-type ATTR cardiac amyloidosis was confirmed by cardiac biopsy and genetic analysis. This case highlights the importance of recognizing MVO along with PJF as a possible morphology in patients with ATTR cardiac amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.